Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Promoting Activity and Cognitive Enrichment in Schizophrenia (PACES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04143126
Recruitment Status : Recruiting
First Posted : October 29, 2019
Last Update Posted : October 6, 2020
Sponsor:
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Shaun M. Eack, University of Pittsburgh

Brief Summary:
This project will conduct a confirmatory efficacy trial of two novel psychosocial interventions, Cognitive Enhancement Therapy and Enriched Supportive Therapy, for the treatment of persistent negative symptoms in schizophrenia.

Condition or disease Intervention/treatment Phase
Schizophrenia Behavioral: Cognitive Enhancement Therapy Behavioral: Enriched Supportive Therapy Not Applicable

Detailed Description:
This project will conduct a confirmatory efficacy trial to examine the efficacy of Cognitive Enhancement Therapy (CET) and Enriched Supportive Therapy (EST) for the treatment of schizophrenia patients with significant and persistent negative symptoms. A total of 90 stabilized schizophrenia outpatients with moderate-to-severe persistent negative symptoms will be randomized to 18 months of CET or EST. Comprehensive data on persistent negative symptoms, social and non-social cognition, and functional outcome will be collected prior to treatment and at frequent 6-month intervals to (1) confirm the efficacy of CET and EST for improving persistent negative symptoms; (2) confirm the impact of cognitive target engagement on reduced negative symptoms; and (3) examine the short-term durability of CET and EST effects on negative symptoms and functioning.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This proposed study consists of an 18-month randomized-controlled trial in which 90 outpatients with schizophrenia with moderate-to-severe persistent negative symptoms will be randomized to Cognitive Enhancement Therapy (CET) or Enriched Supportive Therapy (EST) and treated for 18 months. Comprehensive measures of cognition, negative symptoms, and functional outcome will be collected prior to treatment, every 6-months thereafter (6 and 12 months), at treatment completion (18 months), and 3-month post-treatment follow-up (21 months) to provide a rigorous confirmatory test of the efficacy of CET and EST for patients with persistent negative symptoms and the cognitive mechanisms of negative symptom improvement in the disorder.
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cognitive Enhancement for Persistent Negative Symptoms in Schizophrenia
Actual Study Start Date : October 1, 2019
Estimated Primary Completion Date : March 30, 2024
Estimated Study Completion Date : June 30, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: Cognitive Enhancement Therapy

This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.

Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only

Behavioral: Cognitive Enhancement Therapy
An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
Other Name: CET

Active Comparator: Enriched Supportive Therapy

This research treatment uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.

Time commitment: about 2 hours per week; Location: Pittsburgh, PA only

Behavioral: Enriched Supportive Therapy
An 18-month intervention that uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
Other Name: EST




Primary Outcome Measures :
  1. Change in Persistent Negative Symptoms [ Time Frame: Prior to treatment, 6 months, 12, months, 18 months, and 21 months ]
    Negative symptoms will be assessed using the Clinical Assessment Interview for Negative Symptoms (CAINS). The CAINS is a structured interview measure of expressive and motivational negative symptoms consisting of 13 items based on a standardized interview with anchor points for each rating. This measure was developed to address the limitations of previous negative symptom measures and designed for use in clinical trials of negative symptom therapeutics. This outcome has two endpoints that will be evaluated in this trial, persistent negative symptoms related to expression (Expression subscale) and persistent negative symptoms related to motivation/pleasure (Motivation/Pleasure subscale). Items are rated on a 0 to 4 scale, with higher scores indicating greater negative symptom severity.


Secondary Outcome Measures :
  1. Change in Functioning [ Time Frame: Prior to treatment, 6 months, 12, months, 18 months, and 21 months ]
    A composite index of functional outcomes will be derived from measures of social adjustment commonly used in schizophrenia research. These are clinical interview-based measures of functioning, with some self-report measures, covering vocational, social, family, and other functional outcome domains. Measures will include the Social Adjustment Scale-II, Major Role Adjustment Inventory, the Global Assessment of Functioning, and other field standards of functional outcome in schizophrenia. Because these measures do not share a common Unit of Measure and because of the large number of functional outcome measures used, a composite index will be formed to assess changes in functioning to reduce Type I error from multiple inference testing.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Inclusion criteria will be evaluated longitudinally in a 4-week evaluation period. Patients will be included if they are outpatients and:

  1. are between 18-50 years of age;
  2. have a diagnosis of schizophrenia or schizoaffective disorder confirmed by the SCID;
  3. have a clinical history of persistent negative symptoms lasting at least 3 months as identified from the medical record;
  4. have observed persistent negative symptoms at the beginning and end of the 4-week evaluation period;
  5. have been stabilized on antipsychotic medication at the beginning and end of the 4-week evaluation period;
  6. have stabilized depressive symptoms at the beginning and end of the 4-week evaluation period;
  7. have mild or absent extrapyramidal symptoms at the beginning and end of the 4-week evaluation period;
  8. have had changes to their primary antipsychotic medication within the previous 3 months;
  9. have current IQ > 80; and
  10. are able to read (sixth grade level or higher) and speak fluent English. -

Exclusion Criteria:

Exclusion criteria are intended to avoid likely treatment confounders and contraindications and include:

  1. the presence of organic brain syndrome;
  2. comorbid medical disorders producing cognitive impairment (e.g., mild brain injury, previous concussions with loss of consciousness);
  3. persistent suicidal or homicidal behavior;
  4. significant clinician-estimated medication non-adherence; and
  5. SCID-verified substance use disorder.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04143126


Contacts
Layout table for location contacts
Contact: Shaun M Eack, PhD 412-246-5958 sme12@pitt.edu
Contact: Michelle M Perrin, MBA 412-683-7524 perrinm@upmc.edu

Locations
Layout table for location information
United States, Pennsylvania
University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Shaun Eack, PhD       sme12@pitt.edu   
Principal Investigator: Shaun Eack, PhD         
Sponsors and Collaborators
University of Pittsburgh
National Institute of Mental Health (NIMH)
Layout table for additonal information
Responsible Party: Shaun M. Eack, Professor, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT04143126    
Other Study ID Numbers: STUDY19050382
R01MH118267 ( U.S. NIH Grant/Contract )
First Posted: October 29, 2019    Key Record Dates
Last Update Posted: October 6, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The proposed study has a data sharing plan consistent with NIH policy. Data will be de-identified before sharing on a need to know basis. Sharing will be executed with an approved data transfer agreement.
Time Frame: Final data that has not yet been published will be shared after acceptance of publication of the relevant paper.
Access Criteria: Data sharing will occur at two levels:1) specific requests to analyze data from investigators in the field and 2) collaboration with NIH to facilitate data sharing activities for the NIMH National Database for Clinical Trials Related to Mental Illness (NDCT).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Shaun M. Eack, University of Pittsburgh:
Negative Symptoms
Cognition
Social Cognition
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders